Abstract presented at EHA2022 describing a study of zanubrutinib in acalabrutinib-intolerant patients
with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary safety and efficacy of BGB-11417, a potent
and selective BCL2 inhibitor, in patients with acute myeloid leukemia (AML).
Report on targeted and immune-directed therapies in B-cell malignancies presented at ASCO, EHA and ICML 2021.
Report on recent developments in the treatment of B-cell malignancies presented at ASCO, EHA and ICML 2021.
